Lokken Investment Group LLC Cuts Position in Eli Lilly and Company $LLY

Lokken Investment Group LLC lessened its holdings in Eli Lilly and Company (NYSE:LLY) by 3.5% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,419 shares of the company’s stock after selling 197 shares during the period. Eli Lilly and Company makes up approximately 1.6% of Lokken Investment Group LLC’s portfolio, making the stock its 18th biggest holding. Lokken Investment Group LLC’s holdings in Eli Lilly and Company were worth $4,225,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Hobbs Wealth Management LLC lifted its holdings in shares of Eli Lilly and Company by 0.8% during the first quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company’s stock valued at $1,205,000 after purchasing an additional 12 shares during the last quarter. Hixon Zuercher LLC lifted its holdings in shares of Eli Lilly and Company by 0.7% during the first quarter. Hixon Zuercher LLC now owns 1,789 shares of the company’s stock valued at $1,477,000 after purchasing an additional 12 shares during the last quarter. O Brien Wealth Partners LLC increased its position in shares of Eli Lilly and Company by 25.5% during the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company’s stock valued at $49,000 after acquiring an additional 12 shares in the last quarter. Ascent Capital Management LLC increased its position in shares of Eli Lilly and Company by 2.5% during the first quarter. Ascent Capital Management LLC now owns 495 shares of the company’s stock valued at $409,000 after acquiring an additional 12 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners increased its position in shares of Eli Lilly and Company by 2.7% during the first quarter. Tennessee Valley Asset Management Partners now owns 493 shares of the company’s stock valued at $407,000 after acquiring an additional 13 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

LLY has been the subject of several analyst reports. UBS Group reduced their price target on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating for the company in a research report on Friday, August 8th. JPMorgan Chase & Co. reduced their price target on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating for the company in a research report on Tuesday, September 16th. Cantor Fitzgerald set a $925.00 price target on shares of Eli Lilly and Company and gave the company an “overweight” rating in a research report on Thursday. HSBC raised their price target on shares of Eli Lilly and Company from $700.00 to $800.00 in a research report on Wednesday, October 1st. Finally, Daiwa America downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 17th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $948.56.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, Director Jamere Jackson purchased 200 shares of the company’s stock in a transaction dated Friday, August 8th. The shares were acquired at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the purchase, the director directly owned 9,402 shares of the company’s stock, valued at $6,013,143.12. The trade was a 2.17% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Daniel Skovronsky purchased 1,000 shares of the company’s stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the purchase, the executive vice president directly owned 137,660 shares in the company, valued at approximately $87,331,504. The trade was a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 4,514 shares of company stock worth $2,894,841. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Up 1.0%

NYSE:LLY opened at $854.40 on Friday. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $937.00. The company has a market cap of $808.66 billion, a PE ratio of 55.84, a price-to-earnings-growth ratio of 1.18 and a beta of 0.47. The company has a 50 day simple moving average of $740.99 and a two-hundred day simple moving average of $766.49.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to analysts’ expectations of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company’s revenue was up 37.6% compared to the same quarter last year. During the same quarter last year, the company posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.